Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNissay Asset Management Corp /japan/ /adv
Latest Disclosed Ownership71,463 shares
Latest Disclosed Value $ 31,911,088
Nissay Asset Management Corp /japan/ /adv reports 2.64% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Nissay Asset Management Corp /japan/ /adv filed a 13F-HR form disclosing ownership of 71,463 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $31,911,088 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 69,627 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 2.64% during the quarter. The current value of the position is $31,931,812 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 71,463 1,836 2.64 31,911 1.09 0.1691
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,627 2,970 4.46 31,566 20.92 0.1642
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 66,657 1,019 1.55 26,106 -10.67 0.1442
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 65,638 1,828 2.86 29,222 -5.54 0.1710
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 63,810 5,568 9.56 30,936 29.94 0.2011
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 58,242 2,879 5.20 23,807 -7.54 0.1452
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 55,363 3,996 7.78 25,748 6.94 0.1630
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 51,367 5,242 11.36 24,077 24.88 0.1594
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 46,125 10,167 28.27 19,281 31.78 0.1336
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 35,958 3,260 9.97 14,631 28.67 0.1177
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,698 2,190 7.18 11,370 5.91 0.1008
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,508 -218 -0.71 10,736 10.91 0.0926
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,726 -884 -2.80 9,681 6.05 0.0865
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,610 -1,204 -3.67 9,128 -3.93 0.0872
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,814 1,036 3.26 9,501 6.10 0.0998
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,778 3,085 10.75 8,955 19.59 0.0891
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,693 106 0.37 7,488 19.27 0.0652
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,587 1,026 3.72 6,278 25.59 0.0481
2021-11-10 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,561 1,102 4.16 4,999 -6.30 0.0424
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,459 1,508 6.04 5,335 -0.50 0.0468
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,951 -624 -2.44 5,362 -11.28 0.0529
2021-02-08 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 25,575 -1,184 -4.42 6,044 -17.00 0.0909
2020-10-20 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,759 -4,776 -15.15 7,282 -20.46 0.1230
2020-07-27 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,535 1,794 6.03 9,155 29.36 0.1777
2020-05-05 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,741 805 2.78 7,077 11.70 0.1802
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,936 -1,199 -3.98 6,336 24.11 0.1408
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,135 1,919 6.80 5,105 -1.33 0.1263
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,216 -1,016 -3.48 5,174 -3.78 0.1308
2019-05-03 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,232 -1,112 -3.66 5,377 6.94 0.1421
2019-02-06 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,344 798 2.70 5,028 -11.71 0.1532
2018-10-30 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,546 690 2.39 5,695 16.13 0.1532
2018-08-08 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,856 -1,277 -4.24 4,904 -0.14 0.1435
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,133 -1,206 -3.85 4,911 4.60 0.1535
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,339 31,339 4,695 0.1430
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.